Australian National Amyloidosis Day May 8, 2024 – video now available
May 8, Australian National Amyloidosis Day is a very important day for raising awareness about the group of complicated relatively rare diseases, referred to as amyloidosis. This year the Australian [...]
Tafamidis for ATTR CA listed on the PBS from May 1
PBS listing of Vyndamax®(tafamidis) 61mg for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) with NYHA Class I-II heart failure. For more detailed information use this link to the PBS website. Then [...]
AAN Mayo Clinic Travel Grant Winners
Congratulations to the three young researchers who are heading to the International Symposium of Amyloidosis at the Mayo Clinic on AAN travel grants Photo by Leslie Beasley on Unsplash The AAN Board [...]
Consensus recommendations on holistic care in hereditary ATTR amyloidosis
Hereditary transthyretin-mediated amyloidosis is a rare, progressive and potentially life- limiting multisystem disease, affecting every aspect of a patient’s life. This online international Delphi survey aimed to evolve clinical−patient-led practical [...]
Saluting Professor Philip Hawkins
The AAN was very proud to run inaugural AGM on 24th November. It signified a lot to us and reminded us of how far we come as an organisation. We invited [...]
Introducing the AAN Blog
Hello and welcome to our AAN blog designed to post items by you and for you, about all things amyloid! We welcome blog submissions from all quarters of our amyloid [...]
Introducing the AAN Blog v2
Hello and welcome to our AAN blog designed to post items by you and for you, about all things amyloid ! We welcome blog submissions from all quarters of our [...]